3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Glioma
3
Glioblastoma
3
Lung Neoplasms
2
Astrocytoma
2
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma
1
Ependymoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cisplatin
11
Pemetrexed
10
pembrolizumab
9
Nivolumab
3
LMB-100
3
budigalimab
2
belinostat
2
amatuximab
2
Paclitaxel
2
Docetaxel
2
Dexamethasone
2
Cyclophosphamide
2
Carboplatin
2
Calcium Dobesilate
2
venetoclax
1
trametinib
1
tislelizumab
1
tazemetostat
1
talazoparib
1
spartalizumab
1
sodium thiosulfate
1
sargramostim
1
ruxolitinib
1
rovalpituzumab tesirine
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
irinotecan sucrosofate
1
fludarabine
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Mesothelioma
×
Valacyclovir
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled